Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics Inc.
|
||
| ||
|
Nachrichten in diesem Thema |
Aptevo Therapeutics Inc. - von boersenkater - 12.11.2020, 15:54
RE: Aptevo Therapeutics Inc. - von boersenkater - 12.11.2020, 16:01
|
Möglicherweise verwandte Themen… | |||||
Thema | Verfasser | Antworten | Ansichten | Letzter Beitrag | |
Five Prime Therapeutics | boersenkater | 2 | 1.265 |
02.08.2021, 08:35 Letzter Beitrag: boersenkater |
|
Mirati Therapeutics | Honnete | 0 | 732 |
20.06.2021, 19:57 Letzter Beitrag: Honnete |
|
Sarepta Therapeutics | Ca$hmandt | 1 | 1.472 |
08.01.2021, 20:29 Letzter Beitrag: Ca$hmandt |
Benutzer, die gerade dieses Thema anschauen: 1 Gast/Gäste